Valuation: Edesa Biotech, Inc.

Market Cap 5.54Cr 4.74Cr 4.42Cr 4.06Cr 7.63Cr 530.01Cr 7.78Cr 52Cr 20Cr 265.62Cr 21Cr 20Cr 879.37Cr P/E 2026 *
-2.9x
P/E 2027 * -2.94x
Enterprise Value 5.54Cr 4.74Cr 4.42Cr 4.06Cr 7.63Cr 530.01Cr 7.78Cr 52Cr 20Cr 265.62Cr 21Cr 20Cr 879.37Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.26%
Yield 2026 *
-
Yield 2027 * -
1 day-19.83%
1 week-15.29%
Current month-9.98%
1 month-20.96%
3 months-57.91%
6 months+475.00%
Current year+223.94%
1 week 4.59
Extreme 4.59
6.67
1 month 4.5
Extreme 4.5
6.67
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Free

Founder

5,324 0.0553%
02/07/26 Free

Founder

3,378 0.0380%
04/03/26 Buy

Founder

1,000 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
-20.35%-15.29%+95.28%-22.69% 5.54Cr
+2.38%+5.57%+86.02%+115.89% 7.22TCr
+0.87%+17.34%+57.17%+94.08% 6.4TCr
-3.92%-0.19%-2.60%+473.11% 2.85TCr
+3.63%+8.62%+66.69%+23.95% 2.51TCr
-1.35%+21.35%+0.44%-4.89% 2.84TCr
-0.51%+5.73%+38.71%-14.19% 2TCr
-1.79%-4.51%+241.26%+414.48% 1.82TCr
+1.81%+0.85%+16.89%+546.06% 1.6TCr
-0.85%+6.74%+42.68%+152.78% 1.35TCr
Average -1.95%+5.92%+64.25%+177.86% 2.86TCr
Weighted average by Cap. +0.50%+7.48%+61.18%+162.20%

Financials

2026 *2027 *
Net sales - -
Net income -1.75Cr -1.5Cr -1.4Cr -1.29Cr -2.42Cr -167.92Cr -2.46Cr -17Cr -6.48Cr -84Cr -6.59Cr -6.45Cr -278.6Cr -2.79Cr -2.39Cr -2.23Cr -2.05Cr -3.85Cr -267.14Cr -3.92Cr -26Cr -10Cr -133.88Cr -10Cr -10Cr -443.23Cr
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
20/26/20 $4.620 -19.65% 2,71,194
19/26/19 $5.750 +0.70% 1,19,833
18/26/18 $5.710 +1.06% 49,133
17/26/17 $5.650 +5.61% 1,23,367
14/26/14 $5.350 -1.47% 46,135
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.750USD
Average target price
16.33USD
Spread / Average Target
+184.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock